

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	10/714,078	
				Filing Date	November 14, 2003	
				First Named Inventor	Gunars Valkirs	
				Art Unit	1641	
				Examiner Name	Lisa V. Cook	
Sheet				1	Of	3
				Attorney Docket Number	36671-743.503	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/L.C./	1.	US 2004/0072805 A1	04/15/2004	Warren et al.		
	2.	US 4,447,545	05/08/1984	DeFazio et al.		
	3.	US 5,294,537	03/15/1994	Batt		
	4.	US 5,350,842	09/27/1994	Norgard		
	5.	US 6,268,223 B1	07/31/2001	Cornell-Bell et al.		
/L.C./	6.	US 6,586,244 B2	07/01/2003	Reinhard et al.		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² - Number ³ - Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
/L.C./	7.	WO 03/002553 A2	01/09/2003	Haffner et al.		
	8.	WO 03/002553 A3	03/27/2003	Haffner et al.		
	9.	WO 96/032648 A1	10/17/1996	Spectral Diagnostics		
	10.	WO 02/023191 A1	03/12/2002	Christopherson et al.		
/L.C./	11.	WO 99/018442 A1	04/12/1999	Dalesandro		

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/L.C./	12.	BAKER, M. In biomarkers we trust? Nat Biotechnol. 2005 Mar;23(3):297-304.
/L.C./	13.	BAST, et al. Translational crossroads for biomarkers. Clin Cancer Res. 2005 Sep 1;11(17):6103-8.

Examiner Signature	/Lisa Cook/	Date Considered	06/19/2008
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/714,078
				Filing Date	November 14, 2003
				First Named Inventor	Gunars Valkirs
				Art Unit	1641
Examiner Name	Lisa V. Cook				
Attorney Docket Number	36671-743.503				
Sheet	2	Of	3		

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/L.C./	14.	CHRISTOU, et al. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. Stroke. 2000 Aug;31(8):1812-6.
	15.	CORTI, et al. Vasoepitidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation. 2001 Oct 9;104(15):1856-62.
	16.	Definition of "tissue." Webster's II New Riverside University Dictionary, 1994, by Houghton Mifflin Company, page 1212.
	17.	FEINBERG, et al. Guidelines for the management of transient ischemic attacks. Stroke. June 1994;25(6): 1320-1335.
	18.	International Search Report dated 12/20/2002 for PCT Application No. US2002/26604
	19.	JONES, et al. Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Blood. 2003 Sep 1;102(5):1641-8.
	20.	LABAER, J. So, you want to look for biomarkers (introduction to the special biomarkers issue). J Proteome Res. 2005 Jul-Aug;4(4):1053-9.
	21.	LEE, et al. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain. 1999 Feb;122 (Pt 2):191-7.
	22.	LIU, et al. Changes of von Willebrand factor and antithrombin III levels in acute stroke: difference between thrombotic and haemorrhagic stroke. Thromb Res. 1993 Nov 15;72(4):353-8.
/L.C./	23.	MUN-BRYCE, et al. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol. 1998 May;274(5 Pt 2):R1203-11.

Examiner Signature	/Lisa Cook/	Date Considered	06/19/2008
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/714,078
				Filing Date	November 14, 2003
				First Named Inventor	Gunars Valkirs
				Art Unit	1641
Examiner Name	Lisa V. Cook				
Sheet	3	Of	3	Attorney Docket Number	36671-743.503

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/L.C./	24.	NORMAN, et al. Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry. Biochem Biophys Res Commun. 1991;175(1): 22-30.
	25.	SVIRI, et al. Brain natriuretic peptide and cerebral vasospasm in subarachnoid hemorrhage. Clinical and TCD correlations. Stroke. 2000 Jan;31(1):118-22.
	26.	TARKOWSKI, et al. Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol. 1997 Dec;110(3):492-9.
	27.	VANDER, et al. Human Physiology by McGraw Hill, Sixth Edition, 1994, pages 214, 215, and 230.
/L.C./	28.	WALTHER, et al. Biochemical analysis of neutral endopeptidase activity reveals independent catabolism of atrial and brain natriuretic peptide. Biol Chem. 2004 Feb;385(2):179-84.

Examiner Signature	/Lisa Cook/	Date Considered	06/19/2008
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.